KalVista Presented Additional Analyses Of Efficacy And Safety Of Sebetralstat From Phase 2 And Phase 3 Double-blind, Placebo-controlled Crossover Clinical Trials As Well As Interim Data From KONFIDENT-S, A Phase 3 Open-label Extension Trial

Benzinga · Sep 6 18:35

Data was presented at the Bradykinin Symposium 2024 taking place in Berlin, Germany, on September 5-6. Sebetralstat is a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adult and pediatric patients aged 12 years and older.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

KalVista Presented Additional Analyses Of Efficacy And Safety Of Sebetralstat From Phase 2 And Phase 3 Double-blind, Placebo-controlled Crossover Clinical Trials As Well As Interim Data From KONFIDENT-S, A Phase 3 Open-label Extension Trial

Risk Disclaimer